Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Tipranavir (Aptivus®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0707. 2007 Authors' conclusions Tipranavir (Aptivus®) should be recommended for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection, only for the treatment of highly pre-treated adult patients who have failed multiple protease inhibitors (PI), and where resistance profiling suggests it is appropriate.
Use should be in accordance with the British HIV Association (BHIVA) guidance.
Tipranavir (Aptivus®) is not presently recommended for shared care. Indexing Status Subject indexing assigned by CRD MeSH Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; Humans; Pyridines; Pyrones Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000458 Date abstract record published 08/08/2012 |